ScreenerHero

ALZN Alzamend Neuro, Inc.

NAS · US · Healthcare · Biotechnology · alzamend.com
1.370USD0.00%Mkt Cap: 6.61M $P/E: —

Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which deli…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap6.61M USD
Enterprise Value-980.20K USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-8.77M USD
Revenue/Share—
Last Price1.370 USD
Fiscal Year EndApr 2026
MR QuarterJul 2026
Employees4
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.57
PEG—
EV/EBITDA0.11
EV/Revenue—
P/S—
P/B1.14
EPS (TTM)-2.30
EPS (Forward)-0.87
52W Range
0.840029% of range2.680
52W High2.680 USD
52W Low0.8400 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-1196.43%
ROA-421.88%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-8.07M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-51.93%
Net Debt-7.59M USD
Net Debt/EBITDA0.85
Balance Sheet
Debt/Equity—
Current Ratio3.01
Quick Ratio2.77
Book Value/Sh1.20 USD
Cash/Share1.57 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:9
Split DateMay 12, 2025
Analyst Consensus
Rating—
Target (Mean)26.00 USD
Upside (mean)+1797.8%
Target Range26.00 USD – 26.00 USD
# Analysts1
Ownership
Shares Out.4.83M
Float4.81M
Insiders2.66%
Institutions56.35%
Short Interest
Short Ratio0.9d
Short % Float2.62%
Short % Out.2.55%
Shares Short123.02K
Short (prev mo.)176.57K
Technical
SMA 501.599 (-14.3%)
SMA 2001.558 (-12.1%)
Beta0.27
S&P 52W Chg16.45%
Avg Vol (30d)109.55K
Avg Vol (10d)87.82K
Technical Indicators
RSI (14)36.1
MACD-0.0495
MACD Signal0.0184
MACD Hist.-0.0679
BB Upper2.106 USD
BB Middle1.689 USD
BB Lower1.273 USD
BB Width49.29%
ATR (14)0.1270 USD
Vol Ratio (20d)0.18x